- Relation of MS patients’ diseases duration, vaccination, and medications intake with their psychological health.
| Factors | Psychological disorder | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Normal | Depression | Anxiety | Depression & anxiety | ||||||
| No | (%) | No | (%) | No | (%) | No | (%) | ||
| Duration of MS | |||||||||
| <2 years | 11 | (9.4) | 7 | (6.0) | 1 | (.9) | 98 | (83.8) | .026* |
| 2-5 years | 18 | (10.5) | 17 | (9.9) | 10 | (5.8) | 126 | (73.7) | |
| 5-10 years | 11 | (5.5) | 18 | (9.0) | 1 | (.5) | 169 | (84.9) | |
| > 10 years | 18 | (7.2) | 27 | (10.8) | 11 | (4.4) | 195 | (77.7) | |
| Received covid vaccine | |||||||||
| Yes | 57 | (8.3) | 67 | (9.8) | 21 | (3.1) | 540 | (78.8) | .049*$ |
| No | 1 | (1.9) | 2 | (3.8) | 2 | (3.8) | 48 | (90.6) | |
| Medications used | |||||||||
| Gilenya | 15 | (12.5) | 10 | (8.3) | 4 | (3.3) | 91 | (75.8) | .490$ |
| Tysabri | 3 | (5.2) | 6 | (10.3) | 1 | (1.7) | 48 | (82.8) | |
| Betaferon | 9 | (8.0) | 18 | (15.9) | 5 | (4.4) | 81 | (71.7) | |
| Ocrevus | 7 | (9.5) | 4 | (5.4) | 1 | (1.4) | 62 | (83.8) | |
| Tecfidera | 8 | (14.0) | 6 | (10.5) | 3 | (5.3) | 40 | (70.2) | |
| Mavenclad | 0 | (0.0) | 0 | (0.0) | 1 | (25.0) | 3 | (75.0) | |
| Aubagio | 2 | (3.4) | 3 | (5.2) | 1 | (1.7) | 52 | (89.7) | |
| Rebif | 3 | (4.8) | 8 | (12.7) | 1 | (1.6) | 51 | (81.0) | |
| Mayzent | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 2 | (100.0) | |
| Copaxone | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 4 | (100.0) | |
| Mitoxantrone | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 4 | (100.0) | |
| Lemtrada | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 5 | (100.0) | |
| Others | 10 | (9.3) | 11 | (10.3) | 4 | (3.7) | 82 | (76.6) | |
| None | 3 | (3.3) | 8 | (8.8) | 3 | (3.3) | 77 | (84.6) | |
| Dont know | 2 | (6.3) | 1 | (3.1) | 0 | (0.0) | 29 | (90.6) | |
| Use vitamin D | |||||||||
| Yes | 42 | 7.5% | 54 | 9.7% | 17 | 3.0% | 445 | 79.7% | .891 |
| No | 16 | 8.9% | 15 | 8.3% | 6 | 3.3% | 143 | 79.4% | |